Literature DB >> 31375993

Right ventricular dysfunction is superior and sufficient for risk stratification by a pulmonary embolism response team.

Yu Lin Chen1,2, Colin Wright3,4, Anthony P Pietropaoli3,5, Ayman Elbadawi3,6, Joseph Delehanty4, Bryan Barrus7, Igor Gosev7, David Trawick3,5, Dhwani Patel8, Scott J Cameron3,4,7.   

Abstract

Several risk stratification tools are available to predict short-term mortality in patients with acute pulmonary embolism (PE). The presence of right ventricular (RV) dysfunction is an independent predictor of mortality and may be a more efficient way to stratify risk for patients assessed by a Pulmonary Embolism Response Team (PERT). We evaluated 571 patients presenting with acute PE, then stratified them by the pulmonary embolism severity index (PESI), by the BOVA score, or categorically as low risk (no RV dysfunction by imaging), intermediate risk/submassive (RV dysfunction by imaging), or high risk/massive PE (RV dysfunction with sustained hypotension). Using imaging data to firstly define the presence of RV strain, and plasma cardiac biomarkers as additional evidence for myocardial dysfunction, we evaluated whether PESI, BOVA, or RV strain by imaging were more appropriate for determining patient risk by a PERT where rapid decision making is important. Cardiac biomarkers poorly distinguished between PESI classes and BOVA stages in patients with acute PE. Cardiac TnT and NT-proBNP easily distinguished low risk from submassive PE with an area under the curve (AUC) of 0.84 (95% CI 0.73-0.95, p < 0.0001), and 0.88 (95% CI 0.79-0.97, p < 0.0001), respectively. Cardiac TnT and NT-proBNP easily distinguished low risk from massive PE with an area under the curve (AUC) of 0.89 (95% CI 0.78-1.00, p < 0.0001), and 0.89 (95% CI 0.82-0.95, p < 0.0001), respectively. In patients with RV dysfunction, the predicted short-term mortality by PESI score or BOVA stage was lower than the observed mortality by a two-fold order of magnitude. The presence of RV dysfunction alone in the context of acute PE is sufficient for the purposes of risk stratification. More complicated risk stratification tools which require the consideration of multiple clinical variables may under-estimate short-term mortality risk.

Entities:  

Keywords:  BOVA score; Biomarker; Pulmonary Embolism Response Team (PERT); Pulmonary Embolism Severity Index (PESI); Pulmonary embolism (PE); Right ventricle (RV)

Mesh:

Substances:

Year:  2020        PMID: 31375993      PMCID: PMC6954969          DOI: 10.1007/s11239-019-01922-w

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  34 in total

1.  Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.

Authors:  Michael R Jaff; M Sean McMurtry; Stephen L Archer; Mary Cushman; Neil Goldenberg; Samuel Z Goldhaber; J Stephen Jenkins; Jeffrey A Kline; Andrew D Michaels; Patricia Thistlethwaite; Suresh Vedantham; R James White; Brenda K Zierler
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

2.  The implementation of a pulmonary embolism response team in the management of intermediate- or high-risk pulmonary embolism.

Authors:  Eleftherios S Xenos; George A Davis; Qiang He; Amanda Green; Susan S Smyth
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2019-03-29

3.  A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland Clinic.

Authors:  Jamal H Mahar; Ihab Haddadin; Divyajot Sadana; Abishek Gadre; Natalie Evans; Deborah Hornacek; Natalia Fendrikova Mahlay; Marcelo Gomes; Douglas Joseph; Maya Serhal; Michael Zhen-Yu Tong; Seth R Bauer; Michael Militello; Bernard Silver; Mehdi Shishehbor; John R Bartholomew; Gustavo A Heresi
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

4.  2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.

Authors:  Stavros V Konstantinides; Adam Torbicki; Giancarlo Agnelli; Nicolas Danchin; David Fitzmaurice; Nazzareno Galiè; J Simon R Gibbs; Menno V Huisman; Marc Humbert; Nils Kucher; Irene Lang; Mareike Lankeit; John Lekakis; Christoph Maack; Eckhard Mayer; Nicolas Meneveau; Arnaud Perrier; Piotr Pruszczyk; Lars H Rasmussen; Thomas H Schindler; Pavel Svitil; Anton Vonk Noordegraaf; Jose Luis Zamorano; Maurizio Zompatori
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

Review 5.  Patient Assessment: Clinical Presentation, Imaging Diagnosis, Risk Stratification, and the Role of Pulmonary Embolism Response Team.

Authors:  Tamir Friedman; Ronald S Winokur; Keith B Quencer; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2018-06-04       Impact factor: 1.513

Review 6.  B-type natriuretic peptide as a marker of heart failure: new insights from biochemistry and clinical implications.

Authors:  Marc Vanderheyden; Chris Vrints; Sofie Verstreken; Jozef Bartunek; Jan Beunk; Marc Goethals
Journal:  Biomark Med       Date:  2010-04       Impact factor: 2.851

7.  Expression of natriuretic peptide in ventricular myocardium of failing human hearts and its correlation with the severity of clinical and hemodynamic impairment.

Authors:  E Arbustini; A Pucci; M Grasso; M Diegoli; R Pozzi; A Gavazzi; G Graziano; C Campana; C Goggi; L Martinelli
Journal:  Am J Cardiol       Date:  1990-10-15       Impact factor: 2.778

8.  Identification of intermediate-risk patients with acute symptomatic pulmonary embolism.

Authors:  Carlo Bova; Olivier Sanchez; Paolo Prandoni; Mareike Lankeit; Stavros Konstantinides; Simone Vanni; David Jiménez
Journal:  Eur Respir J       Date:  2014-04-02       Impact factor: 16.671

9.  Contemporary Management and Outcomes of Patients with Massive and Submassive Pulmonary Embolism.

Authors:  Eric Secemsky; Yuchiao Chang; C Charles Jain; Joshua A Beckman; Jay Giri; Michael R Jaff; Kenneth Rosenfield; Rachel Rosovsky; Christopher Kabrhel; Ido Weinberg
Journal:  Am J Med       Date:  2018-08-11       Impact factor: 4.965

10.  Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism.

Authors:  D Aujesky; A Perrier; P-M Roy; R A Stone; J Cornuz; G Meyer; D S Obrosky; M J Fine
Journal:  J Intern Med       Date:  2007-06       Impact factor: 8.989

View more
  7 in total

1.  The safety and efficacy of systemic versus catheter-based therapies: application of a prognostic model by a pulmonary embolism response team.

Authors:  Jean-Pierre Iskandar; Essa Hariri; Christopher Kanaan; Nicholas Kassis; Hayaan Kamran; Denise Sese; Colin Wright; Mark Marinescu; Scott J Cameron
Journal:  J Thromb Thrombolysis       Date:  2021-09-29       Impact factor: 2.300

2.  Left Ventricle Outflow Tract Velocity-Time Index and Right Ventricle to Left Ventricle Ratio as Predictors for in Hospital Outcome in Intermediate-Risk Pulmonary Embolism.

Authors:  Elena Emilia Babes; Manuela Stoicescu; Simona Gabriela Bungau; Diana Uivarosan; Delia Mirela Tit; Mirela Marioara Toma; Alexa Florina Bungau; Cristiana Bustea
Journal:  Diagnostics (Basel)       Date:  2022-05-13

3.  Acute pulmonary embolism in patients with obstructive sleep apnea: frequency, hospital outcomes, and recurrence.

Authors:  Zeynep Idil Seckin; Haytham Helmi; Timothy J Weister; Augustine Lee; Emir Festic
Journal:  J Clin Sleep Med       Date:  2020-07-15       Impact factor: 4.062

4.  Clinical factors associated with massive pulmonary embolism and PE-related adverse clinical events.

Authors:  Praveen Hariharan; Nicholas Giordano; Alona Muzikansky; Christopher Kabrhel
Journal:  Int J Cardiol       Date:  2021-01-31       Impact factor: 4.164

5.  Simultaneous Pulmonary Artery Pressure and Left Ventricle Stroke Volume Assessment Predicts Adverse Events in Patients With Pulmonary Embolism.

Authors:  Hayaan Kamran; Essa H Hariri; Jean-Pierre Iskandar; Aditya Sahai; Ihab Haddadin; Serge C Harb; Joseph Campbell; Leben Tefera; Joseph M Delehanty; Gustavo A Heresi; John R Bartholomew; Scott J Cameron
Journal:  J Am Heart Assoc       Date:  2021-09-06       Impact factor: 5.501

6.  CHA2 DS2 -VASc and PESI scores are associated with right ventricular dysfunction on computed tomography pulmonary angiography in patients with acute pulmonary thromboembolism.

Authors:  Toktam Alirezaei; Zahra Mahboubi-Fooladi; Rana Irilouzadian; Ali Saberi Shahrbabaki; Haniyeh Golestani
Journal:  Clin Cardiol       Date:  2022-02-07       Impact factor: 2.882

7.  Effect of platelet inhibitors on thrombus burden in patients with acute pulmonary embolism.

Authors:  Joseph Van Galen; Libia Pava; Colin Wright; Ayman Elbadawi; Annelise Hamer; Abhishek Chaturvedi; Scott J Cameron
Journal:  Platelets       Date:  2020-03-06       Impact factor: 3.862

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.